Key result
Nanoparticles show targeted potential for plaque stabilization and anti-inflammatory therapy in atherosclerosis.
Nanomedicine holds significant potential for targeted atherosclerosis therapy, though clinical translation is currently limited by manufacturing and regulatory challenges.
Advances in nanotechnology have opened new avenues for precision therapy, personalized medicine, and multifunctional theranostics in atherosclerosis (AS). This review provides a comprehensive overview of the role of nanoparticles (NPs) in precision medicine for AS, discussing their applications, challenges, and future prospects. The review first analyzes the current treatment landscape of AS and outlines potential biological targets for therapy. Various nanocarriers, including organic, inorganic, and hybrid systems, are evaluated for their therapeutic potential, with a focus on targeted drug delivery, anti-inflammatory therapy, vascular repair, plaque stabilization, and lipid clearance. Additionally, the review explores NP preparation methods, emphasizing strategies to enhance drug loading, stability, and controlled release. Finally, the translational challenges of NP-based therapies, including biocompatibility, large-scale production, regulatory hurdles, and clinical implementation, are critically analyzed. Future directions highlight the importance of interdisciplinary collaboration and technological innovation in advancing nanoparticle-based precision medicine for AS.
No takes yet. Share an insight, caveat, or question.
Gu et al. (2025) conducted a review in Atherosclerosis. Nanoparticles (NPs) was evaluated. Nanoparticles offer potential for precision medicine in atherosclerosis through targeted drug delivery, anti-inflammatory therapy, and plaque stabilization, despite translational challenges.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: